| Schedule of Segment Information |
The following tables present our segment information for the 13 and 39 weeks ended September 30, 2023 and October 1, 2022 (in $000’s):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thirteen Weeks Ended |
|
Thirty-Nine Weeks Ended |
|
September 30, 2023 |
|
October 1, 2022 |
|
September 30, 2023 |
|
October 1, 2022 |
| Revenues |
|
|
|
|
|
|
|
| Biotechnology |
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
| Discontinued operations |
— |
|
|
8,587 |
|
|
3,795 |
|
|
28,449 |
|
| Total Revenues |
$ |
— |
|
|
$ |
8,587 |
|
|
$ |
3,795 |
|
|
$ |
28,449 |
|
| Gross profit |
|
|
|
|
|
|
|
| Biotechnology |
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
| Discontinued operations |
— |
|
|
1,034 |
|
|
(197) |
|
|
4,536 |
|
| Total Gross profit |
$ |
— |
|
|
$ |
1,034 |
|
|
$ |
(197) |
|
|
$ |
4,536 |
|
| Operating income (loss) |
|
|
|
|
|
|
|
| Biotechnology |
$ |
(764) |
|
|
$ |
(611) |
|
|
$ |
(2,923) |
|
|
$ |
(1,950) |
|
| Discontinued operations |
— |
|
|
(1,214) |
|
|
14,158 |
|
|
8,016 |
|
| Total Operating income (loss) |
$ |
(764) |
|
|
$ |
(1,825) |
|
|
$ |
11,235 |
|
|
$ |
6,066 |
|
| Depreciation and amortization |
|
|
|
|
|
|
|
| Biotechnology |
$ |
363 |
|
|
$ |
— |
|
|
$ |
1,090 |
|
|
$ |
— |
|
| Discontinued operations |
— |
|
|
77 |
|
|
96 |
|
|
347 |
|
| Total Depreciation and amortization |
$ |
363 |
|
|
$ |
77 |
|
|
$ |
1,186 |
|
|
$ |
347 |
|
| Interest (income) expense, net |
|
|
|
|
|
|
|
| Biotechnology |
$ |
(758) |
|
|
$ |
(410) |
|
|
$ |
(1,598) |
|
|
$ |
(575) |
|
| Discontinued operations |
— |
|
|
280 |
|
|
181 |
|
|
698 |
|
| Total Interest expense, net |
$ |
(758) |
|
|
$ |
(130) |
|
|
$ |
(1,417) |
|
|
$ |
123 |
|
| Net income (loss) before income taxes |
|
|
|
|
|
|
|
| Biotechnology |
$ |
(267) |
|
|
$ |
217 |
|
|
$ |
(1,094) |
|
|
$ |
2,609 |
|
| Discontinued operations |
— |
|
|
(2,182) |
|
|
13,976 |
|
|
5,518 |
|
| Total Net income before income taxes |
$ |
(267) |
|
|
$ |
(1,965) |
|
|
$ |
12,882 |
|
|
$ |
8,127 |
|
|